Clinical Trial Update: Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a four-drug combination of gemcitabine hydrochloride, rituximab, oxaliplatin, and lenalidomide for relapsed or refractory aggr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Auxilio Mutuo Cancer Center | Conditions: Lymphoma | Phase 2 | Status: UNKNOWN